Liudmila V Fedorova

5PUBLICATIONS
15CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 12, 2025
Five-Year Follow-Up of Patients With Relapsed and Refractory Classic Hodgkin Lymphoma Treated With Low-Dose Nivolumab (40 mg): A Matched Cohort Study With Standard-Dose Therapy.

Liudmila Fedorova, Kirill Lepik, Polina Kotselyabina

|Nov 18, 2024
Prognosis of patients with Hodgkin lymphoma and indeterminate response to PD-1 inhibitor therapy: considerations for application of LYRIC criteria in real clinical practice.

Liudmila Fedorova, Kirill Lepik, Artem Gusak

|Oct 26, 2022
[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].

V I Vorobyev, E G Gemdzhian, L V Fedorova

|Nov 26, 2021
Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.

Liudmila V Fedorova, Kirill V Lepik, Nikita P Volkov

|Feb 02, 2021
Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma.

Liudmila V Fedorova, Kirill V Lepik, Natalia B Mikhailova

Pageof 1

Frequent Collaborators

1 joint publications

V I Vorobyev

1 joint publications

E G Gemdzhian

1 joint publications

N B Mikhailova

1 joint publications

R K Ilyasov